AB Science SA

AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company

06 Mar 2024 14:21:09 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

01 Mar 2024 12:07:34 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

29 Feb 2024 05:49:23 By Nasdaq GlobeNewswire

AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS

26 Feb 2024 12:32:14 By Nasdaq GlobeNewswire

AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency

26 Jan 2024 12:01:21 By Nasdaq GlobeNewswire

AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis

15 Jan 2024 12:06:57 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease

28 Nov 2023 13:22:40 By Nasdaq GlobeNewswire

AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

27 Nov 2023 02:04:30 By Nasdaq GlobeNewswire

AB Science today reports its revenues for the first half of 2023 and provides an update on its activities

29 Sep 2023 13:49:30 By Nasdaq GlobeNewswire

AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS

18 Sep 2023 12:05:35 By Nasdaq GlobeNewswire

AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)

26 Jun 2023 12:11:42 By Nasdaq GlobeNewswire

AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037

01 Jun 2023 12:01:02 By Nasdaq GlobeNewswire

AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit

17 May 2023 14:14:57 By Nasdaq GlobeNewswire

AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter

09 May 2023 12:06:29 By Nasdaq GlobeNewswire

AB Science reports its revenues for the year 2022 and provides an update on its activities

28 Apr 2023 12:41:27 By Nasdaq GlobeNewswire

AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting

27 Apr 2023 14:41:14 By Nasdaq GlobeNewswire

AB Science announces the success of its capital increase by private placement for an amount of 15 million euros

24 Apr 2023 02:05:09 By Nasdaq GlobeNewswire

AB Science announces the implementation of a new strategy and the launch of a capital increase

21 Apr 2023 16:26:19 By Nasdaq GlobeNewswire

AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037

18 Apr 2023 12:55:51 By Nasdaq GlobeNewswire

AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline

12 Apr 2023 12:23:23 By Nasdaq GlobeNewswire